Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Novartis Lp(a) drug fails closely watched ph. 3 trial
Lp(a) is a known cardiovascular risk factor, but lowering it in the 8,323-patient trial didn't reduce the risk of heart attacks and strokes.
Darren Incorvaia
Sep 4, 2026 9:18pm
Ultragenyx fails ph. 3 Angelman test as shares tumble
Sep 3, 2026 7:10am
Alumis crushed by midstage lupus flop but plots path to phase 3
Sep 1, 2026 9:27am
BioNTech, Genentech cancel ph. 2 test of personalized cancer vax
Aug 28, 2026 1:50pm
Regeneron ends eye disease trial following safety review
Aug 17, 2026 2:30pm
AstraZeneca ends phase 3 cancer trial as bispecific underwhelms
Aug 17, 2026 4:45am
